Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
Viemed Healthcare Inc. (NASDAQ: VMD) delivers innovative respiratory care solutions through its home-based medical equipment and therapy services. This dedicated news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Access timely updates on earnings reports, product launches, and strategic partnerships that shape VMD's leadership in respiratory disease management. Our curated collection features official press releases alongside verified third-party analysis, ensuring comprehensive coverage of the company's home therapy innovations and equipment rental operations.
Key focus areas include updates on non-invasive ventilation technologies, sleep apnea treatment advancements, and partnerships with healthcare systems. Track developments in Medicare reimbursement policies affecting home care services and monitor VMD's expansion in neuromuscular disease management markets.
Bookmark this page for streamlined access to Viemed Healthcare's latest financial disclosures, regulatory filings, and clinical outcome reports. Stay informed about critical updates through our organized presentation of enterprise-wide developments in respiratory care innovation.
Viemed Healthcare, Inc. (VMD) has announced its acquisition of Home Medical Products, Inc. (HMP) for approximately $31.75 million, expected to close in June 2023. HMP, a Tennessee-based provider of respiratory-focused home medical solutions, generated net revenues of around $28 million and an adjusted EBITDA of $6.8 million in 2022. The acquisition aims to enhance Viemed's growth strategy and expand its patient-centered care approach, with HMP's leadership team joining Viemed post-transaction. Funding will be sourced from cash reserves and undrawn credit facilities. This strategic move is designed to leverage synergies between the two companies, aiming for improved healthcare outcomes for patients.
Viemed Healthcare (NASDAQ: VMD) will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, at 2:30 PM ET in Toronto, Ontario.
The conference aims to connect investors with insights from Canadian healthcare leaders. Viemed’s CEO Casey Hoyt and COO Todd Zehnder will discuss the company's operations and recent developments.
Registered attendees can schedule one-on-one meetings with management. A live webcast of the presentation will be available, with a replay accessible for 90 days post-event.
Viemed specializes in home medical equipment and post-acute respiratory healthcare services, delivering therapy through advanced technology. For more details, visit www.viemed.com.
Viemed Healthcare reported a record net revenue of $37.5 million for Q4 2022, marking a 30% increase year-over-year. Total net revenues for 2022 reached $138.8 million, including COVID-19 services. The company posted $2.4 million in net income for Q4 and $6.2 million for the year. Adjusted EBITDA stood at $9.3 million for Q4 and $30 million for the entire year. Despite a decline in cash balance to $16.9 million, Viemed remains debt-free, having repurchased 1.8 million shares at an average price of $5.33. Looking ahead, Viemed expects revenues of $38.0-$39.0 million for Q1 2023.
Viemed Healthcare, Inc. (NASDAQ: VMD) will host its Year End Conference Call on March 3, 2023, at 11:00 a.m. ET. The conference call is open to financial professionals, who must pre-register by emailing investorinfo@viemed.com by March 2, 2023. Participants can join via phone or through a live audio webcast. A replay will be available afterward on the Viemed website. As a leader in respiratory care and home medical equipment, Viemed focuses on providing effective in-home treatment using advanced technology.
Viemed Healthcare (NASDAQ:VMD) announced a favorable ruling from a U.S. Administrative Law Judge, overturning disputed claims related to a previous audit by the Department of Health and Human Services (HHS). The decision restored 100% of previously remitted funds to Viemed and reaffirmed the integrity of its clinical protocols. The audit had originally found that 98% of patient claims did not meet Medicare requirements, but the ALJ's ruling resulted in zero overpayment for the addressed claims. Viemed plans to communicate the ruling's implications to ensure patients continue receiving necessary care.
Viemed Healthcare (VMD) announced a strategic investment of $2 million in ModoHealth, aimed at enhancing patient management and value-based care. The investment will fund the expansion of ModoHealth’s proprietary network, which integrates clinical tools, remote monitoring, and patient engagement. Viemed will receive an 18-month secured convertible promissory note and plans to leverage its expertise to improve outcomes for patients with respiratory issues like COPD and sleep apnea through ModoHealth's platform. This partnership reflects Viemed’s commitment to innovate in home healthcare delivery.
Viemed Healthcare, Inc. (NASDAQ:VMD) announced new syndicated credit facilities, featuring a senior secured revolving credit facility of up to $30 million and a delayed draw term loan of the same amount. The total borrowing capacity could reach $90 million due to an accordion feature. This move allows the company to enhance its financial flexibility and support future acquisitions, following the retirement of its previous credit facility. The company aims to use these proceeds primarily for refinancing existing debts, acquisitions, working capital, and capital expenditures.
Viemed Healthcare (NASDAQ:VMD) reported record net revenues of $35.8 million for Q3 2022, marking a 28% increase from Q3 2021. The company also achieved a sequential growth of 7% over the previous quarter. Ventilator patient count rose to 9,127, an 11% increase year-over-year. Adjusted EBITDA reached $7.0 million for Q3, totaling $20.7 million for the nine months ended September 30, 2022. Despite a decline in cash balance to $21.5 million from $28.4 million, the company anticipates Q4 revenues of $37.1 million to $38.1 million.
Viemed Healthcare, Inc. (NASDAQ:VMD) will host its Quarterly Conference Call on November 2, 2022 at 11:00 a.m. ET. Interested parties can join by calling 877-407-6176 (US) or 201-689-8451 (International).
Financial professionals are encouraged to pre-register by emailing investorinfo@viemed.com by 12:00 p.m. ET on November 1, 2022.
A live audio webcast will also be available, with replays accessible on Viemed's website following the call.
Viemed Healthcare, a provider of in-home medical equipment and post-acute respiratory care in the U.S., will present at Lake Street's 4th Annual Best Ideas Growth Conference on September 17, 2020. CEO Casey Hoyt and COO Todd Zehnder will engage with investors through one-on-one and group meetings. This invitation-only event features around 90 public growth companies and top institutional investors nationwide. For inquiries or to schedule meetings, contact Lake Street at conference@lakestreetcm.com.
FAQ
What is the current stock price of Viemed Healthcare (VMD)?
What is the market cap of Viemed Healthcare (VMD)?
